Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
27 Apr 2020
Long-term use of brivaracetam as an adjunctive treatment is well tolerated and effective in patients with focal seizures or primary generalized seizures, as shown in a study.
01 Apr 2019
Perampanel is safe and effective for treating refractory focal seizures in both Asian and non‐Asian populations, a study has found.
Rachel Soon, 24 Apr 2018

MIMS Pharmacist presents an overview of CoQ10's physiological role, as well as contemporary research on its pharmacology and effects.

Switching between biologic classes improves drug survival in psoriasis patients

17 Dec 2019

Biologic therapies for psoriasis may need to be switched between classes to increase drug survival in patients, suggest a recent study. Ad hoc retrospective studies are needed to confirm the benefits of this switching strategy.

“Biologic therapy for psoriasis is effective but not always long-lasting and sometimes needs to be switched,” the investigators said.

Of the 195 psoriasis patients included in this study, 90.6 percent achieved a reduction of ≥75 percent in their baseline Psoriasis Area and Severity Index (PASI) score. Ustekinumab (47/169; 27.8 percent) was the most commonly used biologic in 2018. Furthermore, those with higher baseline PASI scores had a higher likelihood of switching biologic therapies (odds ratio, 1.08; p=0.0399).

Drug survival with ustekinumab was longer (>7.0 years) in naïve patients, but no significant differences were seen in biologic-experienced patients. Prior treatment with biologic therapies increased the need for switching (hazard ratio [HR], 1.20; p=0.14). In addition, drug survival was longer when switching between biologic classes than when switching within biologic classes (HR, 0.48; p=0.003).

This study retrospectively observed 195 patients with psoriasis who were treated during 2006–2018. The investigators performed descriptive statistical analyses and logistic regression models. They also used Kaplan–Meier survival curves and multivariable Cox models adjusted for confounding variable to estimate and compare drug survival.

The study was limited by its single-centre, retrospective real-life design, which produced data that were “not perfectly homogenous.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
27 Apr 2020
Long-term use of brivaracetam as an adjunctive treatment is well tolerated and effective in patients with focal seizures or primary generalized seizures, as shown in a study.
01 Apr 2019
Perampanel is safe and effective for treating refractory focal seizures in both Asian and non‐Asian populations, a study has found.
Rachel Soon, 24 Apr 2018

MIMS Pharmacist presents an overview of CoQ10's physiological role, as well as contemporary research on its pharmacology and effects.